Skip to main content

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

Written by Customer Service on . Posted in Public Companies.

ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at three upcoming congresses: the 14th C1-Inhibitor Deficiency and Angioedema Workshop, to be held from May 29-June 1, 2025, in Budapest; the 2025 Eastern Allergy Conference (EAC), to be held from May 29-June 1, 2025, in Palm Beach, Fl.; and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, to be held from June 13-16, 2025, in Glasgow.

Details of the presentations are as follows:
C1-Inhibitor Deficiency and Angioedema Workshop, Budapest, May 29-June 1, 2025.

  • Title: Clinical Validation of a Novel Biomarker Assay to Characterize Bradykinin-Mediated Angioedema in Prospective and Biobank Plasma Samples
    Presenter: Evangelia Pardali, Ph.D.
    Format: Oral Presentation, O-02
    Date, time: Friday, May 30, 8:45-9:00 CEST (2:45-3:00 a.m. ET)
  • Title: Long-Term Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life and Disease Control in Participants With Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study
    Presenter: Markus Magerl, M.D.
    Format: Poster Presentation, P-19
    Date, time: Friday, May 30, 15:45-17:30 CEST (9:45-11:30 a.m. ET)
  • Title: Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant XR Tablet for Prophylaxis of Hereditary Angioedema Attacks: Results of a Pharmacokinetics Study in Healthy Volunteers
    Presenter: Zhi-Yi Zhang, Ph.D.
    Format: Poster Presentation, P-20
    Date, time: Friday, May 30, 15:45-17:30 CEST (9:45-11:30 a.m. ET)
  • Title: Acquired Angioedema Due to C1-Inhibitor Deficiency: Patient Experience and Assessment of Patient-Reported Outcome Measures
    Presenter: Andrea Zanichelli, M.D., Ph.D.
    Format: Poster Presentation, P-17
    Date, time: Friday, May 30, 15:45-17:30 CEST (9:45-11:30 a.m. ET)
  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study
    Presenter: Emel Aygören-Pürsün, M.D.
    Format: Oral Presentation, O-33
    Date, time: Saturday, May 31, 15:30-15:45 CEST (9:30-9:45 a.m. ET)
  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
    Presenter: Marc A. Riedl, M.D., M.S.
    Format: Oral Presentation, O-34
    Date, time: Saturday, May 31, 15:45-16:00 CEST (9:45-10:00 a.m. ET)
  • Title: Durability Of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks
    Presenter: Anna Valerieva, M.D., Ph.D.
    Format: Poster Presentation, P-56
    Date, time: Saturday, May 31, 16:45-17:45 CEST (10:45-11:45 a.m. ET)
  • Title: CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
    Presenter: Andrea Zanichelli, M.D., Ph.D.
    Format: Poster Presentation, P-42
    Date, time: Saturday, May 31, 16:45-17:45 CEST (10:45-11:45 a.m. ET)
  • Title: Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study
    Presenter: Ramón Lleonart, M.D.
    Format: Poster Presentation, P-55
    Date, time: Saturday, May 31, 16:15-17:45 CEST (10:15-11:45 a.m. ET)
  • Title: Epidemiology of Bradykinin-Mediated Angioedema in the European Population
    Presenter: Emel Aygören-Pürsün, M.D.
    Format: Poster Presentation, P-30
    Date, time: Saturday, May 31, 16:15-17:45 CEST (10:15-11:45 a.m. ET)

2025 Eastern Allergy Conference, Palm Beach, Fl., May 29-June 1, 2025.

  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
    Presenter: John Anderson, M.D.
    Format: Poster Presentation
    Date, time: Friday, May 30, 9:45-11:00 a.m. ET
  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
    Presenter: John Anderson, M.D.
    Format: Poster Presentation
    Date, time: Friday, May 30, 9:45-11:00 a.m. ET

EAACI Congress 2025, Glasgow, June 13-16, 2025.

  • Title: Clinical Validation of a Novel Kinin Biomarker Assay for Characterization of Bradykinin-Mediated Pathologies in U.S. Subjects with Hereditary Angioedema
    Presenter: Evangelia Pardali, Ph.D.
    Format: Flash Talk (e-Poster), Abstract #000949, FT03
    Date, time: Friday, June 13, 13:15-14:45 BST (8:15-9:45 a.m. ET)
  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
    Presenter: Emel Aygören-Pürsün, M.D.
    Format: Thematic Poster Session (e-Poster and Poster Session) Abstract #000070
    Date, time: Saturday, June 14, 12:00-13:00 BST (7:00-8:00 a.m. ET)
  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
    Presenter: Henriette Farkas, M.D., Ph.D., D.Sc.
    Format: Thematic Poster Session (e-Poster and Poster Session), Abstract #000069
    Date, time: Saturday, June 14, 12:00-13:00 BST (7:00-8:00 a.m. ET)
  • Title: Development of a Conceptual Model Supporting a Clinical Outcome Assessment Strategy for Acquired Angioedema due to C1 Inhibitor Deficiency
    Presenter: Andrea Zanichelli, M.D., Ph.D.
    Format: Thematic Poster Session (e-Poster and Poster Session), Abstract #000331
    Date, time: Sunday, June 15, 12:45-13:45 BST (7:45-8:45 a.m. ET)
  • Title: Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study
    Presenter: Anna Valerieva, M.D., Ph.D.
    Format: Flash Talk (e-Poster), Abstract #000076, FT16
    Date, time: Sunday, June 15, 14:00-15:30 BST (9:00-10:30 a.m. ET)
  • Title: CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
    Presenter: William Lumry, M.D.
    Format: Flash Talk (e-Poster), Abstract #000068, FT16
    Date, time: Sunday, June 15, 14:00-15:30 BST (9:00-10:30 a.m. ET)
  • Title: Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema in the CHAPTER-1 Open-Label Extension Study
    Presenter: Markus Magerl, M.D.
    Format: Flash Talk (e-Poster), Abstract #000075, FT16
    Date, time: Sunday, June 15, 14:00-15:30 BST (9:00-10:30 a.m. ET)
  • Title: Health-Related Quality of Life and Clinical Characteristics in People Living with Hereditary Angioedema Prescribed Long Term Prophylaxis Alone and On-Demand Treatment Alone
    Presenter: Laurence Bouillet, M.D., Ph.D.
    Format: Oral Presentation, Abstract #000044, OAS18
    Date, time: Sunday, June 15, 15:45-17:15 BST (10:45 a.m.-12:15 p.m. ET)

The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: https://ir.pharvaris.com/news-events/events-presentations.

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of an oral therapy to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/.

CONTACT: Contact
Maggie Beller
Executive Director, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.